A comparative evaluation of the clinical effectiveness of ciclosporin versus infliximab for acute severe ulcerative colitis was reported recently. 270 patients with acute severe ulcerative colitis that failed to respond to intravenous hydrocortisone within 5 days were randomly allocated to receive infliximab or ciclosporin. No statistically significant differences between groups were noted for quality-adjusted survival, frequency of colectomy, mean time to colectomy, or number of serious adverse events.
Williams, J. G. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol. Hepatol. http://dx.doi.org/10.1016/S2468-1253(16)30003-6
About this article
Cite this article
Leake, I. Treatment for acute severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 13, 436 (2016). https://doi.org/10.1038/nrgastro.2016.112
Experimental and Therapeutic Medicine (2019)